Current objectives regarding treatment of acute myeloid leukemia (AML) include achieving
complete remission (CR) by clinicopathological criteria followed by interrogation for the …

Next generation sequencing (NGS) methods have allowed for unprecedented genomic
characterization of acute myeloid leukemia (AML) over the last several years. Further …

Acute Myeloid Leukemia (AML) is the prototype of cancer genomics as it was the first
published cancer genome. Large-scale next generation/massively parallel sequencing …

Simple Summary Although the majority of patients with acute myeloid leukemia (AML) reach
a morphologic complete remission after high-dose chemotherapy, the majority of them face …

Long non-coding RNAs (lncRNAs) have been shown to involve in a variety of cancers. Our
present study aimed to explore the exact roles of lncRNA LINC00909 (LINC00909) in the …

The present study aimed to examine whether monoclonal immunoglobulin heavy chain
(IGH) or T‑cell receptor (TCR) gene rearrangement in cell‑free DNA (cfDNA) may be used for …

Dapper antagonist of catenin‐3 (DACT3) is a new tumor‐related protein associated with a
diverse set of tumors. However, whether DACT3 plays a role in acute myeloid leukemia …

Measurable/minimal residual disease (MRD) status is the most relevant predictor of clinical
outcome in hematolymphoid neoplasms, including acute myeloid leukemia (AML). In …

This new volume discusses the widespread concerns of hematopoietic challenges in
different and emerging ways. With chapters written by faculty and researchers from …

AML remains incurable four decades after its discovery. AML (t-AML) treatment remained
unchanged without any improvements in outcomes. AML is characterized by cytogenetic …